Instrument Inactif

Autres langues Innovation Pharmaceuticals Inc. Other OTC

Actions

IPIX

US45782D1000

Recherche biotechnologique et médicale

Autres langues

01/02/24	Innovation Pharmaceuticals Inc. Announces Resignation of Board Members
05/12/23	Alfasigma S.p.A. and Innovation Pharmaceuticals Inc. Terminate Exclusive License Agreement
20/11/23	Innovation Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023
28/09/23	Innovation Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended June 30, 2023
28/08/23	Innovation Pharmaceuticals Announces New Milestone at BeaMed; On Track to File 510(k) Submission to FDA in Q2 2024
21/06/23	Innovation Pharmaceuticals Provides Update on U.S. Patent Applications Covering Use of Brilacidin in Inflammatory Bowel Diseases, Coronaviruses and Fungal Diseases
21/06/23	Innovation Pharmaceuticals Provides Update on U.S. Patent Applications Covering Use of Brilacidin in Inflammatory Bowel Diseases, Coronaviruses and Fungal Diseases
05/06/23	Innovation Pharma Announces BeaMed Technologies Breakthrough in Development of Fiber Optic Probes for StingRay Laser System; Paves Way for Groundbreaking Integration Testing
15/05/23	Innovation Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023
17/04/23	Innovation Pharmaceuticals Brilacidin Antifungal Research Published in Nature Communications
15/03/23	Innovation Pharmaceuticals Announces New Antifungal Testing of Brilacidin by NIH/NIAID-Affiliated and Other Academic Researchers
15/03/23	Innovation Pharmaceuticals Announces New Antifungal Testing of Brilacidin by NIH/NIAID Affiliated and Other Academic Researchers
23/02/23	Innovation Pharmaceuticals Visits BeaMed; New StingRay Laser System for Epilepsy and Brain Tumors Moving Toward FDA Submission
15/02/23	INNOVATION PHARMACEUTICALS INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
15/02/23	Innovation Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022
09/01/23	Innovation Pharmaceuticals Announces BT BeaMedical Technologies and Shina Systems Ltd. Enter into a Definitive Strategic Development Agreement
04/01/23	INNOVATION PHARMACEUTICALS INC. : Other Events (form 8-K)
14/12/22	Innovation Pharmaceuticals Reports New In Vivo Antifungal Data Showing Brilacidin's Potential for Treating Fungal Keratitis
13/12/22	Innovation Pharmaceuticals Reports New In Vivo Antifungal Data Showing Brilacidin’s Potential for Treating Fungal Keratitis
13/12/22	Innovation Pharmaceuticals Provides an Update on Ongoing Research on the Broad-Spectrum Antifungal Activity of Brilacidin
28/11/22	Innovation Pharmaceuticals Announces BT BeaMedical Technologies Receives FDA Clearance for New Surgical Laser Family
16/11/22	Scientific Poster on Innovation Pharmaceuticals Brilacidin to be Presented at 2022 Chemical and Biological Defense Science & Technology Conference
10/11/22	INNOVATION PHARMACEUTICALS INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
10/11/22	Innovation Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended September 30, 2022
27/10/22	Innovation Pharmaceuticals - NHS Medical Director for Specialised Services Calls New Laser Technology for Epilepsy 'Game-Changing Breakthrough'